- Conditions
- Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Interventions
- 18F-fluciclovine injection, 18F-FDG PET/CT
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2017–2040
of 3,601
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cancer Prevention, Weight Loss, Smoldering Waldenstrom Macroglobulinemia(WM), MGUS, Fasting, Multiple Myeloma
- Interventions
- Prolonged Fasting Intervention, EDUCATION CONTROL
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Waldenstrom's Macroglobulinemia
- Interventions
- Everolimus, Rituximab, Bortezomib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Refractory Multiple Myeloma
- Interventions
- Tivantinib, Diagnostic laboratory biomarker analysis, Questionnaire administration, Quality-of-life assessment
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Knee Osteoarthritis
- Interventions
- Pure PRP II, PureBMC
- Combination Product
- Lead sponsor
- Andrews Research & Education Foundation
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Gulf Breeze, Florida
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- AUY922, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • San Antonio, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Clofarabine
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- tipifarnib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes, Hematological Malignancies, B-cell Malignancy, Low-grade, Myelodysplastic Syndrome With Low-grade Lesions, IgG Monoclonal Gammopathy of Uncertain Significance, Smoldering Multiple Myeloma, Waldenstrom Macroglobulinemia
- Interventions
- Not listed
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2030
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 4 more
- Conditions
- Multiple Myeloma
- Interventions
- Linvoseltamab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2035
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Orange, California • Denver, Colorado + 9 more
- Conditions
- COVID19, Coronavirus Infection, Coronavirus, Virus Diseases, RNA Virus Infections
- Interventions
- Convalescent Plasma
- Biological
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 31 Days and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- anti-thymocyte globulin, fludarabine phosphate, Melphalan, mycophenolate mofetil, tacrolimus, umbilical cord blood transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Northside Hospital, Inc.
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Interventions
- Acupuncture, Standard of Care CIPN management
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Multiple Myeloma, Neoplasms
- Interventions
- cetuximab, vemurafenib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 11
- States / cities
- Tucson, Arizona • Aurora, Colorado • Boston, Massachusetts + 6 more
- Conditions
- Insulin Resistance, Diabetes Mellitus
- Interventions
- Olanzapine 10 mg po qhs for 3 days, Placebo
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Alzheimer's Disease
- Interventions
- Thalidomide
- Drug
- Lead sponsor
- Banner Health
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Sun City, Arizona
- Conditions
- Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Waldenström Macroglobulinemia
- Interventions
- rituximab, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan
- Biological · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Pomalidomide, All-trans retinoic acid, Dexamethasone
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Lymphoma, Mantle-cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Multiple Myeloma
- Interventions
- ON01910 Na
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Multiple Myeloma
- Interventions
- IMGN901
- Drug
- Lead sponsor
- ImmunoGen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Palm Springs, California • Sarasota, Florida + 6 more
- Conditions
- Healthy Volunteers
- Interventions
- Cardiosyn
- Dietary Supplement
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Congestive Heart Failure
- Interventions
- Blood Volume Analysis, Echocardiogram
- Procedure
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Advanced Solid Tumors, Breast Cancer, Inflammatory Breast Cancer, Castleman's Disease, Multiple Myeloma
- Interventions
- CX-4945 oral formulation
- Drug
- Lead sponsor
- Cylene Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Fort Collins, Colorado • Loveland, Colorado + 1 more
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- bortezomib, hydroxychloroquine
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania